Adalimumab is a fully human monoclonal antibody specific to human TNF-alpha that is approved in the USA (February 2008) and Europe (September 2008) for the treatment of polyarticular JIA and was recently approved for JIA in Japan [13–15]. The gene discussed is TNF; the disease is juvenile idiopathic arthritis.